You have PCOS. You started tirzepatide, and for a while the scale moved. Then it stopped. Each time you told your telehealth prescriber, the reply was a higher dose, and nobody told you why the medication might not be working anymore. You have now made a decision that is fair to make: you do not want to inject anything.
That decision usually comes with a search. Is there such a thing as PCOS care without injections, and if there is, would it be real care or the same arrangement with a different delivery method? This piece answers that question plainly. It explains what a stall can and cannot tell you, what a labs-first membership does about it, what it costs, and where it will not make the promise you might be hoping for.
- A stall on tirzepatide is a question for labs and a clinician, and a higher dose alone cannot answer it.
- The GoodLife Health membership requires no medication at all; medication is prescribed only when a clinician judges it clinically indicated.
- Branded oral options exist, such as the Wegovy pill (from $149 a month at lower doses through NovoCare, September 2026), but no one can promise a pill before a clinician has reviewed you.
- Four cardiometabolic lab panels a year are included; they are blood draws, so a needle is involved, though nothing is injected.
- The membership is $299 a month; $598 at sign-up covers two months, refunded in full if you are not accepted into care and non-refundable once you are accepted.
- The fee is the same at any dose and for any medication, so no one gains from raising yours.
A stalled scale and a dose that only went up
The pattern is a familiar one. Maybe it started with an online form and a prescription, and the early months felt like proof that something had finally worked. When progress slowed, you sent a message. The answer came back as a new strength. When progress slowed again, the answer was the same. At no point did the conversation widen beyond the number on the scale and the number on the prescription.
That pattern has a cost that shows up on the bill. Through LillyDirect, Zepbound vials were priced at $299 to $449 a month depending on dose, as published in September 2026. A higher dose can mean a higher price at the pharmacy, which is a reasonable thing to notice when the higher dose is not giving you a reason to pay it.
The larger cost is the one nobody named. PCOS is part of your history, and you know your health was never only a question of weight. Yet the care you were getting treated weight as the whole story, and treated the dose as the only tool for changing it. When the tool stopped working, there was nothing else in the room.
Without an explanation, you cannot tell whether the stall means the medication is wrong for you, the dose is wrong, or something else is pulling in the other direction. You are left guessing, paying and injecting on a single theory that nobody ever said out loud.
So the injection itself has become the thing you want to stop. That can mean many things. Perhaps the routine has worn you down. Perhaps you no longer trust that a needle is solving the right problem when nobody has shown you what the problem is. You do not need to justify it, and nothing in this piece will try to talk you out of it. What this piece will do is separate two questions that the dose-only approach ran together: whether you should inject something, and why your progress stopped. The second question has to be answered before anyone can answer the first one well.
Why a stall is a question a higher dose cannot answer
A scale tells you that your weight changed or that it did not. It cannot tell you why. A stall is an outcome, and an outcome is not a diagnosis. Treating it as one means reaching for the same lever every time, because without more information there is no other lever to reach for.
The Learning Center's comparison of GLP-1 telehealth models describes most of the market as weight-loss verticals: businesses that compete on access to a molecule and on the price of delivering it. That is a legitimate thing to sell, and it is also a narrow one. The comparison names what such a model is not built to look at: the thyroid quietly stalling a protocol, the fasting insulin rising years before glucose moves, the hormonal picture that may be driving the weight in the first place. If a service is organized around the molecule, the molecule is what it adjusts.
The definitive guide to Cardiometabolic Optimization describes the underlying biology as a chain: insulin resistance drives weight gain, visceral fat disrupts hormones, disrupted hormones stall metabolism, and stalled metabolism feeds vascular inflammation. The guide calls hormonal health the axis most weight-loss platforms skip entirely, and the reason so many protocols stall. With PCOS in your history, the hormone and insulin side of that chain is a reasonable place for a clinician to look before deciding that the answer is more of the same medication.
There is also an incentive question, and it is worth stating carefully. The definitive guide observes that most telehealth platforms earn more when patients are prescribed more, through margin on the molecule or upcharges as the dose rises. That says nothing certain about any single prescriber's judgment, including the one you have been seeing. It does explain why a model built that way has no structural reason to stop and ask whether the dose is the problem. When the fee is the same at every dose, no one in the room gains from raising yours.
What changes the picture is information gathered on a schedule. The guide describes a quarterly re-audit as what turns a prescription from a guess into a feedback loop. Labs drawn before a decision show where you are. Labs drawn again 90 days later show whether the decision did what it was meant to do. Without that loop, a stall leaves two moves: raise the dose or give up. With it, a clinician can look at your insulin markers, your thyroid and your hormones, alongside the scale, before choosing what comes next.
The way results are read matters too. The guide describes reading them against optimal ranges rather than population reference ranges, which is a different question from whether a number happens to be flagged on a printout. A result that nobody flagged can still be part of the explanation you were never given.
This is also where your objection gets an honest answer rather than a reassuring one. You may be right that more injections are not what you need. You may not be. Your preference matters, and a clinician should weigh it. The decision itself should rest on what your labs show and what a clinician concludes from them, and never on a platform's pricing or on a promise made to win your sign-up.
A weight-loss stall on a GLP-1 is a question for labs and a clinician as much as for the dose. If you are taking tirzepatide now, keep taking it as prescribed until a clinician has reviewed your situation, since stopping or changing a medication is a decision to make with one.
When the fee is the same at every dose, no one in the room gains from raising yours.
What the membership does, what it costs, and what it does not do
GoodLife Health is a clinician-led membership: precision direct primary care for Cardiometabolic Optimization, with clinicians licensed in all fifty states. The order matters. Diagnosis comes first, then treatment, then the long haul of following what the treatment does. For someone whose care so far has been a prescription and a dose schedule, that order is the main difference.
Diagnosis before the next prescription
The membership includes four cardiometabolic lab panels a year, and every result goes into your hands. The definitive guide describes the Biomarker Audit as covering ApoB, Lipoprotein(a), hs-CRP, HbA1c and insulin markers, lipids, and full hormone and thyroid panels. A clinician reads those results, and you can reach the care team through asynchronous messaging and through video visits. You see the same numbers your clinician sees, and you can ask what they mean and what they change.
One honest detail, since your objection is about needles: lab panels are drawn, which means a blood draw four times a year. Nothing is injected, but a needle is involved. If that alone rules the membership out for you, it is better to know now than after you have paid.
Where injections fit, and where they may not
The membership does not require you to take any medication. Medication is prescribed only when a clinician judges it clinically indicated, and only branded, FDA-approved medication: Wegovy, Zepbound, Mounjaro or Ozempic for GLP-1; hormone therapy and thyroid medication where indicated; and any FDA-approved medication a clinician judges indicated, sent to the pharmacy you choose.
Not every option is an injection. The Wegovy pill is a branded option you take by mouth, and through NovoCare it was priced from $149 a month at lower doses as of September 2026. The definitive guide also describes an oral generation of GLP-1 medication. Whether any oral option is right for you is a clinical decision, and the right next step may turn out to be a different medication, a change in dose, or no change at all until the labs are back.
What the membership can promise is how the decision is made. The fee is the same whatever medication is indicated and whatever the dose: no molecule upcharge, no dose upcharge. The definitive guide describes doses held at the lowest effective level, and deprescribing, when labs support it, treated as a success rather than a lost sale. Your wish not to inject is something you state in your intake and raise with your clinician. If a clinician still judges an injectable to be the best option, you can ask for the reasoning and talk it through with the care team, with your own lab results in front of you.
What it costs
The membership is $299 a month, month to month. At sign-up, $598 is charged, which covers the first two months. If the clinician cannot accept you into care, the $598 is refunded in full. Once you are accepted, the first two months are non-refundable. Over a year, the membership is $3,588. The fee is generally eligible for HSA or FSA pre-tax dollars.
Medication is unbundled. When something is prescribed, it goes to the pharmacy you choose, at that pharmacy's own price, and medication billed by a pharmacy follows that pharmacy's own return and refund policy. GoodLife Health sets nothing, sees nothing and takes nothing on medication. Using August 2026 prices, the comparison of true GLP-1 telehealth costs puts a GoodLife Health member's all-in monthly cost at the cheapest channel for the dose from $448 on an oral entry dose to $748 at injectable maintenance. Prices move, so treat those figures as dated examples.
The membership pairs with your insurance for catastrophic coverage; it does not replace it. Whether insurance covers a medication is between you, your plan and your pharmacy, and coverage is never promised. Prior authorization is the pharmacy's process, and GoodLife Health does not run it.
What it does not do
It does not promise weight loss, a return to the progress you had, or a particular result of any kind. It does not promise that you will never be prescribed an injection, because no honest service can promise a prescription before a clinician has reviewed you. It does not prescribe compounded GLP-1 in any form. Compounded copies are pharmacy-made, not the FDA-reviewed branded products, and the FDA has published its concerns about unapproved GLP-1 drugs used for weight loss. And it does not accept everyone. The path is the eligibility check, the intake, the checkout, then a clinician's review, and that review can end in a no.
So, do you have to inject anything?
No. Nothing in the membership requires you to inject anything, and medication of any kind is prescribed only when a clinician judges it indicated. The four lab panels a year are blood draws, so a needle is part of the diagnosis even though nothing is injected.
The fuller answer is that your objection deserves to be heard by someone who will also look at why you stalled. A stall after a run of dose increases, with PCOS in your history and no explanation offered, is a reasonable point to stop and gather information. That might lead to an oral medication, a change to what you take now, hormone or thyroid treatment where indicated, or a recommendation you were not expecting. You will have the labs that the recommendation rests on, and you will be able to ask about them.
What you get for $299 a month is the part your care has been missing: a clinician, quarterly labs, every result in your hands, and a fee that does not move when your dose does. What you do not get is a guarantee, because a guarantee is something no clinician can honestly offer for this situation.
Who this is not for
If you want the lowest possible price on a needle-free GLP-1 and no clinical relationship around it, the manufacturers' self-pay channels sell the drug on its own, and the membership adds a cost you may not want. If you want a $99-a-month app, this is not one; GoodLife Health sits between the $20,000-a-year concierge practice and the $99-a-month compounded app, and it says so. If you want compounded GLP-1 or a promise of a specific result, you will not find either here. If you were hoping a membership could stand in for health insurance, it cannot. And if you are not willing to have blood drawn four times a year, a labs-first model will not suit you, because the labs are the point.
Related Reading
- The True Monthly Cost of GLP-1 Telehealth: An Honest Comparison
- Cardiometabolic Optimization: The Definitive Guide
References
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss